mebhydrolin napadisilate

Small moleculeexperimental

Mebhydrolin (INN) or mebhydroline is an antihistamine. It is not available in the United States, but it is in various other countries under the brand names Bexidal (BD) and Diazolin (RU). It is used for symptomatic relief of allergic symptoms caused by histamine release, including nasal allergies and allergic dermatosis. — Wikipedia

Clinical trial activity

1 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1

Earliest trial started Oct 1, 2010 (NCT01584791)

Timeline

No events for the selected filters.

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CN1CCc2c(c3ccccc3n2Cc2ccccc2)C1
Mol. weight
276.38 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 1,5-naphthalenedisulfonic acid, compd. with 2,3,4,5-tetrahydro-2-methyl-5-(phenylmethyl)-1h-pyrido(4,3-b)indole (1:2)
  • 5-benzyl-1,3,4,5-tetrahydro-2-methyl-2h-pyrido(4,3-b)indole
  • diazolin
  • diazoline
  • diazolinum
  • fabahistin
  • fabahistin
  • fabahistin
  • fabahistin
  • fabahistin
  • incidal
  • incidal
  • incidal
  • mebhydrolin
  • mebhydrolin
  • mebhydrolin
  • mebhydrolin
  • mebhydrolin
  • mebhydroline
  • mebhydroline
  • mebhydroline 1,5-naphthalenedisulfonate
  • mebhydrolin napadisilate
  • mebhydrolin napadisylate
  • mebhydrolin napadisylate
  • mebhydrolin napadisylate
  • mebhydrolin napadisylate
  • napadisilate
  • napadisilate
  • omeril
  • omeril
  • omeril

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01584791Phase 4Oct 1, 2010Hanmi Pharmaceutical, Seoul National University
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Hanmi PharmaceuticalFor profit1012010
Seoul National UniversityAcademic/Hospital1112010
2 organizations
Page 1 / 1